PATENT CLAIM ANALYSIS

Application Number: 15761725
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-12
Patent Classification: ["514", "017800"]

Abstract:
The present invention relates to an agent which inhibits Kallikrein-8 for use in the treatment or prevention of Alzheimer's disease and/or its precursor stages, as well as to methods, kits and uses relating thereto, including diagnostic tools.

Claim (Index 14):
An in vitro method of identifying and/or stratifying of at least one individual to be responsive to treatment or prevention of Alzheimer's disease, and/or and/or precursor stages of Alzheimer's disease with an agent which inhibits Kallikrein-8, comprising the steps of:\n (1) detecting the level of Kallikrein-8 protein and/or kallikrein-8 mRNA in a bodily sample of an individual, and (2) comparing the level determined in step (1) with the level(s) determined in one or more reference samples from healthy individuals and/or from patients known to have Alzheimer's disease and/or a precursor stage of Alzheimer's disease, or known to be responsive to treatment or prevention of Alzheimer's disease, and/or precursor stages of Alzheimer's disease with an agent which inhibits Kallikrein-8, wherein an increased level determined in step (1) compared to the level(s) determined in one or more reference samples from healthy individuals, and/or a level determined in step (1) which is identical or similar to the level(s) determined in one or more reference samples from patients\n known to have Alzheimer's disease and/or a precursor stage of Alzheimer's disease, and/or \n known to be responsive to treatment or prevention of Alzheimer's disease, and/or precursor stages of Alzheimer's disease with an agent which inhibits Kallikrein-8 \n indicates that the individual is responsive to treatment or prevention of Alzheimer's disease, and/or precursor stages of Alzheimer's disease with an agent which inhibits Kallikrein-8, more preferably wherein the bodily sample is selected from a bodily fluid sample, in particular selected from cerebrospinal fluid sample, blood sample, such as plasma sample, whole blood sample and serum sample, urine sample and saliva sample, and a biopsy, in particular a brain tissue biopsy, even more preferably the bodily fluid sample is a cerebrospinal fluid sample.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 90.0
- Lexical Diversity: 1.10526
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12157664', '13393220', '14324289', '13701758', '11185907']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7566481693136528
- 35 USC 102 Novelty (BERT): 0.5213575760996095
- Combined Prediction Score: 0.7331191099922484
- Mean Citation Score: 308.592442
- Max Citation Score: 328.3323
- Similarity Product: 242.5064376165033

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test